ExosoMe as Integrative Tool for pRognostic Stratification of Adverse Cardiac remodeLing in stEmi Patients: the MIRACLE Study

Summary

This is a multicenter observational prospective study aimed to assess whether plasma exosomes can help identify, at an early stage, patients at high risk of adverse remodeling after STEMI (ST-elevation myocardial infarction) , thus accelerating proper patient management in order to reduce the risk of future cardiovascular events. In order to study the correlation between exosome profile and severity of myocardial infarction, consecutive STEMI patients will be enrolled 3 days after Percutaneous Coronary Intervention (PCI).

Eligibility

Inclusion Criteria:

* chest pain suggestive of myocardial ischemia lasting \>30 min
* electrocardiogram (ECG) showing ST-segment elevation \>0.1 mV in more or equal to 2 limb leads or \>0.2 mV in more or equal to 2 contiguous precordial leads, or presumed new left bundle-branch block
* successful treatment with pPCI within 12 h from the onset of symptoms

Exclusion Criteria:

* previous myocardial infarction (MI)
* time to pPCI \>12 h
* atrial fibrillation
* renal failure with glomerular filtration \<30 ml/min
* claustrophobia
* other contraindications to CMR.

Conditions2

Browse More Trials